Macro News - The U.S. Treasury reported that from January to August, the national general public budget revenue reached 14,819.8 billion yuan, a year-on-year increase of 0.3% [2] - The securities transaction stamp duty for the same period was 118.7 billion yuan, showing a significant year-on-year increase of 81.7% [2] - In August, the securities transaction stamp duty increased by 226% year-on-year and 66% month-on-month [2] Industry News - The Ministry of Industry and Information Technology is soliciting opinions on the mandatory national standard for "Intelligent Connected Vehicles Combination Driving Assistance System Safety Requirements," which includes features for detecting driver disengagement [3] - The total A-share trading volume for the year has reached 280 trillion yuan, a 109% increase compared to the same period last year [3] - The average daily trading volume in A-shares is 16.1 trillion yuan, up 107% year-on-year [3] - The China Nonferrous Metals Industry Association reported that the transaction price range for multi-crystalline silicon n-type raw materials is 51,000 to 55,000 yuan per ton, with an average transaction price of 53,200 yuan per ton, reflecting an 8.57% increase [4] Company News - Tianpu Co. announced that there is uncertainty regarding the change of control, and its stock will resume trading on September 18 [11] - Hengrui Medicine announced that its application for a new indication for the injection of Rukang Qumizhuo monoclonal antibody for breast cancer patients has been accepted and prioritized for review [11] - China Ping An announced the completion of its long-term service plan for stock purchases for the year 2025 [11] - Top Group announced that its actual controller and vice chairman has terminated the share reduction plan ahead of schedule [11] - Huazhu Group announced a planned investment of no more than 10 billion yuan in bank wealth management products [11]

Core Viewpoint - Anke Biotech (300009.SZ) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the key Phase II clinical trial of PA3-17 injection, a targeted CAR-T cell therapy for adult relapsed and refractory CD7-positive hematological malignancies [1] Group 1 - The PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product to receive clinical trial approval [1] - The product utilizes advanced genetic engineering technology to modify the patient's own T cells, enabling them to specifically recognize and kill CD7-positive tumor cells [1] - The approval marks a significant milestone for Boshengji Anke in the development of innovative cancer therapies [1]

Core Viewpoint - Anke Biotech (300009.SZ) announced that its affiliated companies, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., received approval from the National Medical Products Administration for the key Phase II clinical trial of PA3-17 injection, a targeted CAR-T cell therapy product for treating adult relapsed and refractory CD7-positive hematological malignancies [1]. Group 1 - Anke Biotech's affiliated companies have received a communication meeting minutes from the National Medical Products Administration regarding the PA3-17 injection [1]. - PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product that has received approval for clinical trials [1]. - The product is specifically designed for the treatment of adult patients with relapsed and refractory CD7-positive hematological malignancies [1].

Core Viewpoint - The announcement highlights that the affiliated companies of Anke Bio, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd., have received approval from the National Medical Products Administration (NMPA) for the key Phase II clinical trial of PA3-17 injection, a targeted CAR-T cell therapy product for treating adult relapsed and refractory CD7-positive hematological malignancies [1]. Group 1 - The PA3-17 injection is the world's first CAR-T cell therapy product targeting CD7 that has received clinical trial approval [1]. - The approval allows the applicant to proceed with critical Phase II clinical trials [1]. - The product is specifically designed for adult patients with relapsed and refractory CD7-positive hematological malignancies [1].

安徽安科生物工程（集团）股份有限公司 关于参股公司 PA3-17 注射液获准进入关键性 II 期临床试验的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 近日，安徽安科生物工程（集团）股份有限公司（以下简称"公司"）参股 公司博生吉医药科技（苏州）有限公司、博生吉安科细胞技术有限公司（以下简 称"博生吉安科"）收到国家药品监督管理局药品审评中心（CDE）签发的PA3-17 注射液II期沟通交流会议纪要，同意申请人开展PA3-17注射液关键性II期临床试 验。具体情况如下： 一、该药物基本情况 证券代码：300009 证券简称：安科生物 公告编号：2025-051 2、申请事项：境内生产药品注册临床试验 3、申请人名称：博生吉安科细胞技术有限公司 4、受理号：CXSL2101087 5、审批结论：同意申请人开展 PA3-17注射液关键注册II期临床研究 患者的关键性II期临床试验。 三、风险提示 在获准进入关键性II期临床试验后，博生吉安科将按相关法规规定组织开展 临床试验。由于药品研发的特殊性，药品从临床试验到获准上市的周期长、环节 多，易受到诸多不可预测的 ...

Core Viewpoint - Hefei High-tech Zone aims to become a significant hub for the synthetic biology industry, focusing on innovation in four key areas: biomaterials, biomedicine, bio-agriculture, and bio-foods [2][3]. Group 1: Development Plan - The "Implementation Plan for Synthetic Biology Industry Development" was officially released, emphasizing the importance of resource aggregation and promoting high-end, green development in the industry [2]. - A special fund of no less than 3 billion yuan will be established to support the industrialization of major achievements, alongside collaboration with financial institutions to innovate financial products [2]. Group 2: Industry Foundation - The synthetic biology industry in Hefei High-tech Zone has established a solid foundation, featuring a dual-driven model of "enterprises + platforms" [2]. - Over 30 core enterprises have been cultivated, including Anke Bio, Zhifei Longkema, and Zhaoke Pharmaceutical, covering critical areas such as antibody drugs and new vaccines [2]. Group 3: Future Goals - By 2027, the plan aims to nurture more than 10 enterprises with a production value exceeding 100 million yuan, at least 3 enterprises with over 500 million yuan, and 1 enterprise surpassing 1 billion yuan [3]. - The goal is to gather no less than 50 enterprises in the synthetic biology industry chain, with a total production value exceeding 10 billion yuan [3].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 9 月 15 日（周一）15:00-17:00。届时公司 高管将在线就公司治理、经营状况、发展战略等投资者关心的问题，与投资者进 行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 安徽安科生物工程（集团）股份有限公司 董事会 2025 年 9 月 9 日 网上集体接待日活动的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，安徽安科生物工程（集团）股份有限公 司（以下简称"公司"）将参加由安徽证监局指导，安徽上市公司协会与深圳市 全景网络有限公司联合举办的"2025年安徽上市公司投资者网上集体接待日"活 动，现将相关事项公告如下： 证券代码：300009 证券简称：安科生物 公告编号：2025-050 安徽安科生物工程（集团）股份有限公司 关于参加 2025 年安徽辖区上市公司投资者 ...

Core Viewpoint - Anke Biological has experienced a decline in stock price recently, with a year-to-date increase of 28.47% but a 6.10% drop in the last five trading days [1][2] Company Overview - Anke Biological, established on September 28, 2000, and listed on October 30, 2009, is located in Hefei, Anhui Province. The company specializes in research, development, production, and sales of biotechnological products, including cell engineering, gene engineering, gene testing, and precision medicine [1] - The main revenue sources for Anke Biological are gene engineering drugs (88.24%), topical patches (11.67%), and other supplementary products (0.09%) [1] Financial Performance - For the first half of 2025, Anke Biological reported a revenue of 1.292 billion yuan, a year-on-year decrease of 0.51%, and a net profit attributable to shareholders of 367 million yuan, down 11.92% year-on-year [2] - Since its A-share listing, Anke Biological has distributed a total of 2.662 billion yuan in dividends, with 1.252 billion yuan distributed in the last three years [3] Shareholder Structure - As of June 30, 2025, Anke Biological had 65,700 shareholders, a decrease of 2.17% from the previous period, with an average of 18,598 circulating shares per person, an increase of 2.22% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 20.7916 million shares (an increase of 7.341 million shares), and other notable shareholders such as the China National Securities Bio-Medical Index A and the Southern CSI 1000 ETF [3]

Group 1 - The company Anke Bio (300009.SZ) has stated that it is currently not involved in any business related to brain-computer interfaces [1]